Fig. 5: The activation of MAIT cells ameliorates the disease progression of EAU.
From: Mucosal-associated invariant T cells have therapeutic potential against ocular autoimmunity
a Illustration of a therapeutic strategy for the treatment of uveitis used in this study. b The expressions of Il22 and (c) tissue repair-related genes such as Il19 (left panel) and Ngf (right panel) in eyes on 10 days after EAU induction after treatment with 5-OP-RU or its control (PBS) are shown. The relative values to Actb expression are shown. d The MAIT cell numbers in eyes on 14 days after treatment with 5-OP-RU or its control. e The time course of EAU clinical scores of mice after an intravitreal administration of rIL-22 (0.33 μg/eye) and 5-OP-RU (0.84 pmol/eye) (PBS, n = 11; 5-OP-RU, n = 12; rIL-22, n = 8). f Representative retinal fundus images on day 10, 14, and 17 after immunization. g The histopathological EAU scores on day 17 (PBS, n = 13; 5-OP-RU, n = 13; rIL-22, n = 9). h H&E staining of sections of eyes from the indicated mice. Scale bars: 100 μm. Arrowheads indicate retinal folds (black), perivasculitis (blue), and vasculitis (red). b–e, g *p < 0.05, **p < 0.01 e by one-way ANOVA, followed by Dunnett’s multiple comparison test or b–d, g by Mann–Whitney U-test. e Data are mean ± SEM. Data are representative of three independent experiments.
